Related Experiment Video
Updated: Aug 16, 2026
14:57
Preparation of Acute Hippocampal Slices from Rats and Transgenic Mice for the Study of Synaptic Alterations during Aging and Amyloid Pathology
Published on: March 23, 2011
Brain morphology and response to nortriptyline in geriatric depression
R C Young1, B Kalayam, D E Nambudiri
1The New York Hospital-Cornell Medical Center, Westchester Division, White Plains, New York 10605, USA.
Summary
In older adults with major depression, larger ventricle-brain ratios were linked to a poorer response to nortriptyline treatment. This finding suggests brain structure may influence antidepressant effectiveness in geriatric patients.
Area of Science:
- Geriatric Psychiatry
- Neuroimaging
- Pharmacology
Background:
- Major depression is a prevalent condition in geriatric patients.
- Treatment response in older adults with depression can be variable.
- Brain morphology may play a role in antidepressant efficacy.
Purpose of the Study:
- To investigate the relationship between brain morphology and nortriptyline treatment response in geriatric depression.
- To identify potential neurobiological predictors of antidepressant response in the elderly.
Main Methods:
- A cohort of 15 geriatric patients with major depression was studied.
- Brain morphology was assessed using computed tomography (CT).
- The ventricle-brain ratio was calculated and correlated with treatment response to nortriptyline.
Main Results:
- A significant negative association was found between ventricle-brain ratio and nortriptyline response (rs=-0.63; P=0.015).
- Higher ventricle-brain ratios correlated with lower response rates to nortriptyline.
Conclusions:
- Brain structural changes, specifically increased ventricle-brain ratio, may predict poorer response to nortriptyline in geriatric depression.
- Neuroimaging markers could aid in personalizing depression treatment for older adults.
Related Concept Videos
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...